AbCellera Biologics Stock Forecast

Stock Price Forecast

According to 9 analysts polled by S&P Global, AbCellera Biologics stock has a consensus rating of "Strong Buy" and an average price target of $10.43. The average 1-year stock price forecast is 99.05% higher than the current stock price, while the lowest is $7.00 (+33.59%) and the highest is $13 (+148.09%).

Price Target: $10.43 (+99.05%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$7.00	$10.43	$11	$13
Change	+33.59%	+99.05%	+109.92%	+148.09%

Analyst Ratings

The average analyst rating for AbCellera Biologics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Nov '25	Dec '25	Jan '26	Feb '26	Apr '26	May '26
Strong Buy	6	6	6	6	6	7
Buy	1	1	1	1	1	1
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	8	8	8	8	8	9

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Srikripa Devarakonda Truist Financial	Truist Financial	Buy Reiterates $10 → $12	Buy	Reiterates	$10 → $12	+129.01%	May 22, 2026
Evan Seigerman BMO Capital	BMO Capital	Buy Maintains $7	Buy	Maintains	$7	+33.59%	May 12, 2026
Debanjana Chatterjee JonesTrading	JonesTrading	Buy Reiterates $11 → $13	Buy	Reiterates	$11 → $13	+148.09%	May 12, 2026
Stephen Willey Stifel Nicolaus	Stifel Nicolaus	Buy Reiterates $7 → $8	Buy	Reiterates	$7 → $8	+52.67%	May 12, 2026
Brendan Smith TD Cowen	TD Cowen	Buy Maintains n/a	Buy	Maintains	n/a	n/a	May 12, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

31.99M

from 75.13M

-57.43%

from 75.13M

Revenue Next Year

30.89M

from 31.99M

-3.42%

from 31.99M

EPS This Year

-0.65

from -0.49

EPS Next Year

-0.72

from -0.65

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	375.20M	485.42M	38.03M	28.83M	75.13M	31.99M
Revenue Growth	60.92%	29.38%	-92.17%	-24.17%	160.56%	-57.43%
Operating Income	204.41M	224.91M	-237.21M	-282.77M	-217.10M	-245.61M
Net Income	153.46M	158.52M	-146.40M	-162.86M	-146.41M	-201.32M
EPS	-	-	-	-	-0.49	-0.65
Free Cash Flow	143.80M	205.62M	-102.40M	-177.77M	-176.00M	-137.32M
No. Analysts	-	-	-	-	-	9

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	38.7M
Avg	32.0M
Low	25.8M

Revenue Growth

Revenue Growth	2026	2027	2028
High	-48.5%
Avg	-57.4%
Low	-65.6%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-0.65
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-